February 10, 2006 -- Amylin Pharma reported positive data from a Phase II study of its obesity drug, an analogue to its approved diabetes medication; Accorda Therapeutics priced its IPO, offering 5.5 million shares at $6 each; BioMimetic filed to raise $50 million in its IPO; Penwest Pharma released upbeat news from a Phase IIa trial of an extended release oral pain medication; PDI Inc, an out-sourced sales organization, warned that AstraZeneca may end its relationship with PDI; Pfizer disappointed investors by lowering its sales and earnings forecast for 2006 while touting its new and existing products; Pain Therapeutics made a large percentage gain after being recommended on TV. The Centient Biotech 200™ was 16 points higher at 3875.37, a rise of .42%. More details...
